Tabuk Pharma and Althera Laboratories Announce Strategic Licensing and Supply Agreement for Advanced Type 2 Diabetes Therapy in MENA
Tabuk Pharma has entered into a strategic partnership with Althera Laboratories to introduce an innovative treatment for type 2 diabetes across the MENA region.
This collaboration reinforces Tabuk Pharma’s commitment to expanding value-added therapeutic solutions and enhancing healthcare quality, in alignment with Saudi Vision 2030 and its ambition to advance the pharmaceutical sector and meet the region’s evolving healthcare needs.
For more information, please visit the full announcement.
Click here to read more